253 related articles for article (PubMed ID: 27929198)
1. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
[TBL] [Abstract][Full Text] [Related]
2. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
Neergaard-Petersen S; Hvas AM; Kristensen SD; Grove EL; Larsen SB; Phoenix F; Kurdee Z; Grant PJ; Ajjan RA
Thromb Haemost; 2014 Dec; 112(6):1142-50. PubMed ID: 25187394
[TBL] [Abstract][Full Text] [Related]
3. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity.
Ajjan R; Lim BC; Standeven KF; Harrand R; Dolling S; Phoenix F; Greaves R; Abou-Saleh RH; Connell S; Smith DA; Weisel JW; Grant PJ; Ariëns RA
Blood; 2008 Jan; 111(2):643-50. PubMed ID: 17925485
[TBL] [Abstract][Full Text] [Related]
4. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.
Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148
[TBL] [Abstract][Full Text] [Related]
5. Maturity onset diabetes of the young and fibrin-related thrombosis risk.
Sagar RC; Phoenix F; Thanabalasingham G; Naseem K; Ajjan RA; Owen KR
Diab Vasc Dis Res; 2020; 17(6):1479164120963048. PubMed ID: 33334146
[TBL] [Abstract][Full Text] [Related]
6. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3.
Hess K; Alzahrani SH; Mathai M; Schroeder V; Carter AM; Howell G; Koko T; Strachan MW; Price JF; Smith KA; Grant PJ; Ajjan RA
Diabetologia; 2012 Apr; 55(4):1103-13. PubMed ID: 21918806
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).
Scipione CA; McAiney JT; Simard DJ; Bazzi ZA; Gemin M; Romagnuolo R; Macrae FL; Ariëns RA; Hegele RA; Auld J; Gauld JW; Boffa MB; Koschinsky ML
J Thromb Haemost; 2017 Sep; 15(9):1834-1844. PubMed ID: 28632940
[TBL] [Abstract][Full Text] [Related]
8. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
[TBL] [Abstract][Full Text] [Related]
9. Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.
Gaule TG; Ajjan RA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203139
[TBL] [Abstract][Full Text] [Related]
10. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
Celińska-Lowenhoff M; Iwaniec T; Padjas A; Musiał J; Undas A
Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
[TBL] [Abstract][Full Text] [Related]
11. Partial deletion of the αC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis.
Westbury SK; Duval C; Philippou H; Brown R; Lee KR; Murden SL; Phillips E; Reilly-Stitt C; Whalley D; Ariëns RA; Mumford AD
Thromb Haemost; 2013 Dec; 110(6):1135-44. PubMed ID: 24048413
[TBL] [Abstract][Full Text] [Related]
12. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
13. Interpretation and Validation of Maximum Absorbance Data Obtained from Turbidimetry Analysis of Plasma Clots.
Pieters M; Guthold M; Nunes CM; de Lange Z
Thromb Haemost; 2020 Jan; 120(1):44-54. PubMed ID: 31752041
[TBL] [Abstract][Full Text] [Related]
14. Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes.
Konieczyńska M; Bryk AH; Malinowski KP; Draga K; Undas A
Thromb Haemost; 2017 Aug; 117(9):1671-1678. PubMed ID: 28569923
[TBL] [Abstract][Full Text] [Related]
15. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit.
Undas A; Slowik A; Wolkow P; Szczudlik A; Tracz W
Thromb Res; 2010 Apr; 125(4):357-61. PubMed ID: 19942259
[TBL] [Abstract][Full Text] [Related]
16. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
17. Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study.
Bryk AH; Konieczyńska M; Polak M; Plicner D; Bochenek M; Undas A
Cardiovasc Diabetol; 2021 Feb; 20(1):47. PubMed ID: 33602240
[TBL] [Abstract][Full Text] [Related]
18. Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy.
Nastałek M; Wojas-Pelc A; Undas A
J Thromb Thrombolysis; 2010 Aug; 30(2):121-6. PubMed ID: 20419337
[TBL] [Abstract][Full Text] [Related]
19. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.
Hugenholtz GC; Macrae F; Adelmeijer J; Dulfer S; Porte RJ; Lisman T; Ariëns RA
J Thromb Haemost; 2016 May; 14(5):1054-66. PubMed ID: 26833718
[TBL] [Abstract][Full Text] [Related]
20. Prothrombotic fibrin network characteristics in patients with acromegaly: a novel mechanism for vascular complications.
Kyriakakis N; Pechlivani N; Lynch J; Oxley N; Phoenix F; Seejore K; Orme SM; Ajjan R; Murray RD
Eur J Endocrinol; 2020 May; 182(5):511-521. PubMed ID: 32197236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
